Lipigon Pharmaceuticals AB (publ) (FRA:9RP)
Germany flag Germany · Delayed Price · Currency is EUR
0.0038
+0.0002 (5.56%)
At close: Nov 28, 2025

FRA:9RP Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-35.97-25.26-12.13-37.71-41.11-8.07
Upgrade
Depreciation & Amortization
0.10.060.020.020.02-
Upgrade
Other Operating Activities
0.27-0.230.09-0.02-0.240.25
Upgrade
Change in Accounts Receivable
8.86-1.2-0.52-0.241.83-2.03
Upgrade
Change in Other Net Operating Assets
-1.591.85-1.790.484.211.22
Upgrade
Operating Cash Flow
-28.33-24.78-14.32-37.47-35.3-8.63
Upgrade
Capital Expenditures
-0.11-0.24---0.12-
Upgrade
Investment in Securities
-----1.25
Upgrade
Investing Cash Flow
-0.11-0.24---0.121.25
Upgrade
Issuance of Common Stock
38.184.3843.2722.65619.65
Upgrade
Other Financing Activities
-6.680.2-6.56-3.99-4.91-0.77
Upgrade
Financing Cash Flow
34.324.5836.718.6151.0918.88
Upgrade
Foreign Exchange Rate Adjustments
-0.030.28-0.090.020.24-
Upgrade
Miscellaneous Cash Flow Adjustments
0--0---
Upgrade
Net Cash Flow
5.86-20.1522.29-18.8315.9211.51
Upgrade
Free Cash Flow
-28.44-25.02-14.32-37.47-35.42-8.63
Upgrade
Free Cash Flow Margin
-3227.58%-243.18%-87.27%--1601.94%-215.09%
Upgrade
Free Cash Flow Per Share
--0.18-0.22-2.55-3.93-1.95
Upgrade
Levered Free Cash Flow
-14.32-16.34-10.69-23.57-20.42-5.65
Upgrade
Unlevered Free Cash Flow
-14.15-16.3-10.69-23.57-20.41-5.65
Upgrade
Change in Working Capital
7.270.65-2.310.246.03-0.81
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.